Tirzepatide
Tirzepatide, a prescription medication used to treat Type 2 diabetes, is a GIP and GLP-1 receptor agonist also used for weight loss. It is injected under the skin once a week. Tirzepatide was FDA approved in the United States to treat Type 2 diabetes in May 2022 under the brand name “Mounjaro”. In November 2023, it was approved for weight loss under the brand name “Zepbound”.

Who is a candidate?
Adults 18 years of age or older. Individuals with a BMI of 30 or greater . Individuals with a BMI of 27 or greater, with at least one weight-related health issue

BENEFITS
Appetite suppression. Slows digestion= feeling of fullness. Significant weight loss

Starting Your Journey
Schedule a consultation by reaching out to us via phone or online. We will evaluate your suitability for treatment. If you meet the criteria, your provider may prescribe Tirzepatide. The dose will be increased over 4 to 20 weeks to reach target doses of 5 mg, 10 mg, or 15 mg weekly. We will monitor your progress through follow-up visits and adjust treatment if necessary.

Impressive OUTCOMES
Patients lost an average of 15% to 20% of their starting body weight over 72 weeks (approximately 16.5 months) . Average weight loss of 52 pounds over 72 weeks. Over 20% reduction in starting body weight. Results comparable to those of weight-loss surgery